Recombinant Human Interferon Alpha 2B

Recombinant Human Interferon Alpha 2B (rHuIFN-α2B) is an antiviral and antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2, originally sequenced and produced using recombinant DNA technology in the laboratory of Charles Weissmann at the University of Zurich in 1980. Developed by Biogen and marketed by Schering-Plough as Intron-A, this medication has a wide range of applications, including treating chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, malignant melanoma, and more. Notably, it is also being studied in clinical trials for treating patients with SARS-CoV-2, the virus responsible for COVID-19 . Its cross-species nature allows it to work in non-human animals, although the period of usefulness is limited by the production of antibodies against this foreign protein. In summary, rHuIFN-α2B stands at the forefront of medical advancements, combating both viral infections and cancers.

Transfer of the end-to-end technology available in GMP-like environment.

Recombinant human Interferon alpha 2b (rhIFN alpha 2b) is produced in E.coli using an expression vector driven by the T7 promoter.
Production: 30L fermentation with a yield of around 350 mg/L (unpurified)
Purification: rhIFN alpha 2b will be purified from inclusion bodies by solubilization, refolding and cation exchange chromatography. Final yield of the process is around 30 % (3g of pure protein from the 30L fermentation). The purity of the product is at least 97% by RP-HPLC analysis.

Treatment with interferon supports the functions of the immune system and it is used in the treatment of Chronic Hepatitis, other viral infections and in cancer therapy .